Viking Therapeutics (VKTX)

Viking Therapeutics (VKTX) Financial Statements


Viking Therapeutics Financial Overview

Viking Therapeutics's market cap is currently ―. The company's EPS TTM is $-0.93; its P/E ratio is -72.60; Viking Therapeutics is scheduled to report earnings on July 24, 2024, and the estimated EPS forecast is $-0.27. See an overview of income statement, balance sheet, and cash flow financials.
Mar 24Dec 23Sep 23Jun 23Mar 23
Income Statement-
Total Revenue-----
Gross Profit-----
EBIT$ -27.36M$ 4.48M$ -22.53M$ -19.23M$ -19.53M
EBITDA$ -30.07M$ 33.57M-$ -19.12M$ -19.43M
Net Income Common Stockholders$ -27.36M$ -24.61M$ -22.53M$ -19.23M$ -19.53M
Balance Sheet-
Cash, Cash Equivalents and Short-Term Investments$ 962.98M$ 362.08M$ 376.24M$ 392.92M$ 135.66M
Total Assets$ 967.52M$ 368.49M$ 382.66M$ 400.69M$ 150.90M
Total Debt$ 1.18M$ 1.26M$ 1.34M$ 1.41M$ 1.49M
Net Debt$ -961.79M$ -360.82M$ -374.90M$ -391.51M$ -134.17M
Total Liabilities$ 33.63M$ 20.07M$ 14.42M$ 14.58M$ 16.83M
Stockholders Equity$ 933.89M$ 348.42M$ 368.24M$ 386.12M$ 134.06M
Cash Flow-
Free Cash Flow$ -6.13M$ -17.64M-$ -11.44M$ -24.64M
Operating Cash Flow$ -6.13M$ -17.64M$ -19.66M$ -11.44M$ -24.64M
Investing Cash Flow$ -459.79M$ 35.73M$ -12.53M$ -204.48M$ 2.20M
Financing Cash Flow$ 606.04M$ 188.00K$ -74.00K$ 267.08M$ 4.18M
Currency in USD

Viking Therapeutics Earnings and Revenue History

Viking Therapeutics Debt to Assets

Viking Therapeutics Cash Flow

Viking Therapeutics Forecast EPS vs Actual EPS

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis